YVY Life Sciences of Uruguay said it signed an agreement with Vancouver, Canada-based Blueberries Medical Corp. to jointly develop cannabis genetics, and to replicate YVY’s small-farm cultivation model in Colombia.
YVY said the deal marks a first step in its international strategy, bringing together initiatives in two of Latin America’s leading cannabis nations.
“Our goal is to work closely with Blueberries to replicate YVY’s unique cultivation model with small producers in Colombia, producing high-quality and natural products while generating scalable social and environmental impact,” said Andrea Krell, Chief Executive Officer of YVY. A pilot project is scheduled to begin by the end of 2021.
The partners said they plan to develop genetics in Colombia, and then register them in both countries.
“We are excited with the opportunity to register our top genetics in other countries. Uruguay is the perfect jurisdiction to start our expansion into new geographies and potentially export dry flower, something that is not yet allowed in Colombia,” said Jose Forero, Blueberries President of Latin American Operations
YVY makes cannabis lifestyle products and supports small farmers in Uruguay. The company was founded by Kruchik Krell and Kevin Nafte, a former head of operations at California -based Flow Kana, in 2018.
Blueberries Medical Corp. has interests in agriculture, genetics, extraction, medicine, pharmacology, and marketing of CBD and THC-based medical cannabis, and has sales operations in Colombia and Argentina.
